Artificial intelligence (AI) has the potential to revolutionize the field of pharmacogenomics, impacting drug response prediction and treatment effectiveness. By leveraging AI technology, pharmacogenomics can advance personalized medicine and improve patient outcomes across various conditions, including neurodegenerative disorders, cardiovascular diseases, and cancer.
AI in pharmacogenomics goes beyond traditional methods of genetic testing by providing an AI-based economic framework that considers cost and outcome effectiveness in drug selection. This enables healthcare providers to make more informed decisions and optimize treatment plans for individual patients.
Additionally, AI can enhance data-based outcomes, leading to more accurate coverage policies by payers. By analyzing large datasets and utilizing machine learning algorithms, AI can provide insights into the efficacy and cost-effectiveness of pharmacogenomic interventions, as...
_____
If you are a member of our Association, please log in below to continue reading our exclusive content.
Not a member yet? Discover the benefits of joining our network and gain access to exclusive content like this for only $29.95 per month. Learn More and Sign Up
